Point72 Asset Management’s Palisade Bio PALI Stock Holding History
Bought
Maintained
Sold
Other funds holding PALI
BGI
OCA
PA
CC
RCM
EP
Point72 Asset Management's PALI Position: Q1 2026 in Review
Point72 Asset Management reduced its Palisade Bio (PALI) stake by 96% in Q1 2026, selling an estimated $18.3M and leaving 411,772 shares worth $721K. The position accounts for ﹤0.01% of the portfolio, ranked #2948.
Point72 Asset Management first reported a position in PALI in Q4 2025 and has held it in 2 quarters since. The position peaked at $24.7M in Q4 2025. 96 funds tracked by Wall St. Rank hold PALI as of Q1 2026.
- Point72 Asset Management held 411,772 shares of Palisade Bio worth $721K as of Q1 2026.
- Point72 Asset Management sold 10,083,480 Palisade Bio shares in Q1 2026, an estimated $18.3M.
- Palisade Bio made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #2948 holding.
- Point72 Asset Management first reported a position in Palisade Bio in Q4 2025 and has held it in 2 quarters since.
- Point72 Asset Management's Palisade Bio position peaked at $24.7M in Q4 2025.
- 96 funds tracked by Wall St. Rank held Palisade Bio as of Q1 2026.
Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.